PubMed Health⌕ Search

Biomedical subjects

G Carrara

Publications and source records attributed to G Carrara.

29 records · Page 2Linked to original sources
PubMedDate not supplied

Evaluation of herbicide migration from water to gorgonzola and mozzarella cheeses in industrial processing.

The possibility of migration of atrazine, simazine, terbuthylazine, molinate and bentazon herbicides from contaminated water used in the manufacture of gorgonzola and mozzarella cheeses was verified in an industrial plant in an agricultural area in northern Italy. In a milk-processing plant, water samples were drawn from five wells; samples of milk, curd and finished products were collected from the respective production lines. In all samples, the herbicide residues were detected by gas chromatographic analysis. The results show that herbicide residues detected in water were not found in the finished products even if residues were found in the intermediate products (curd).

Atrazine↗
PubMedDate not supplied

[The retreatment with natural leukocyte interferon alfa-n3 of chronic hepatitis C patients: the intolerant and nonresponsive results to prior treatment with recombinant alfa interferon].

To evaluate leukocyte interferon alpha-n3 tolerability and efficacy in the retreatment of patients with chronic hepatitis C poorly tolerant to previous treatment with recombinant interferon alpha, 142 patients (73 "relapsers" and 69 "nonresponders") were retreated with leukocyte interferon alpha-n3 (6 MU thrice weekly for 6 months) and followed up for 12-42 months. Only patients with complete regression of any previous interferon-related adverse events were included. Three patients dropped out due to recurrence of a severe depressive syndrome. In 104/139 patients (75%) no significant life-style changes vs baseline were observed during retreatment, while 35 subjects experienced moderately negative interference with their living habits. The different influence on the patients' quality of life during leukocyte interferon alpha-n3 treatment in comparison with the previous treatment was significant. In 118 patients (85%) the interferon-related adverse events significantly decreased. After 12 months of follow-up, a sustained biochemical response was observed in 48 patients (35%), and a persistent biochemical and virological response was seen in 33 (23%). The good compliance with leukocyte interferon alpha-n3 administration shown by poorly tolerant patients, "relapsers/nonresponders" to recombinant interferon, permitted retreatment with full doses and thus increased the chance of obtaining a larger number of sustained responses.

Adult↗
PubMedDate not supplied

Management of patients with HCV infection poorly tolerant to recombinant interferon alpha.

BACKGROUND/AIMS: To evaluate leukocyte interferon-alpha tolerability and efficacy in the retreatment of patients poorly tolerant to recombinant interferon-alpha. METHODOLOGY: Patients with chronic hepatitis C, poorly tolerant to a previous interferon-alpha treatment (118 patients; 73 "relapsers": Group I; 45 "non-responders": Group II) were retreated with 6 MU tiw of leukocyte interferon-alpha for 6 months and then followed-up for 12-34 months. Only patients with complete regression of any previous interferon-related adverse event were included. RESULTS: Three patients dropped out due to recurrence of a severe depressive syndrome. In 86/115 patients (75%) no significant lifestyle changes versus baseline were observed during retreatment, while 29 subjects experienced a moderately negative interference on their living habits. The different influence on the patients' quality of life of leukocyte interferon in comparison with the previous treatment was significant (P < 0.001). In 98 patients the interferon-related adverse events significantly decreased. After 12 months of follow-up, a sustained biochemical response was observed in 40 patients (Group I:31; Group II:9), and a persistent virological response in 28 (Group I:23; Group II:5). CONCLUSIONS: The good compliance with leukocyte interferon administration shown by poorly tolerant patients, non-responders/relapsers to recombinant interferon, permitted a retreatment with full doses, so increasing the chance to obtain a larger number of sustained responses.

Adult↗
PubMedDate not supplied

[Effect of iron depletion on long-term response to interferon in patients with chronic hepatitis C with increased plasma iron without accumulation of liver iron].

We studied the effect of iron depletion on the response to subsequent interferon therapy in a population of 83 patients affected by chronic hepatitis C who had not previously undergone any specific therapy and who had laboratory confirmation of iron overload (serum ferritin > 400 ng/mL in the males and > 300 ng/mL in the females). The population was divided into two homogeneous groups. Group A consisted of 43 patients who underwent phlebotomy (300 mL every 10-15 days for an average total of 8 sessions) until serum ferritin levels of < 100 ng/mL were obtained. The 40 patients in Group B were treated with interferon without prior iron depletion. Iron depletion alone, induced in Group A, brought about a highly significant (p < 0.01) reduction of alanine aminotransferase serum values: from 165 U/L (range 60-370 U/L) to 67 U/L (range 27-158 U/L). Seventy-six patients completed therapy and follow-up: a complete and sustained response was obtained in 12/39 cases in Group A and in 6/37 cases in Group B (p < 0.05). Iron depletion carried out in patients with chronic hepatitis C, who have elevated base values of serum ferritin, induces a significant reduction in necro-inflammatory activity (notable decrease in average alanine aminotransferase values) and improves the response to subsequent treatment with interferon, although it does not modify the viral load.

Adult↗